Anatara Lifesciences Valuation

Is ANR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ANR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ANR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ANR's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ANR?

Key metric: As ANR is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ANR. This is calculated by dividing ANR's market cap by their current book value.
What is ANR's PB Ratio?
PB Ratio	8.2x
Book	AU$1.36m
Market Cap	AU$11.19m

ANR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-7x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does ANR's PB Ratio compare to its peers?

The above table shows the PB ratio for ANR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	1.7x
NSB NeuroScientific Biopharmaceuticals	1x	n/a	AU$5.4m
CHM Chimeric Therapeutics	3.3x	n/a	AU$8.1m
TRP Tissue Repair	0.9x	n/a	AU$16.9m
PTX Prescient Therapeutics	1.7x	n/a	AU$29.8m
ANR Anatara Lifesciences	8.2x	n/a	AU$11.2m

Price-To-Book vs Peers: ANR is expensive based on its Price-To-Book Ratio (8.2x) compared to the peer average (1.7x).

Price to Book Ratio vs Industry

How does ANR's PB Ratio compare vs other companies in the AU Biotechs Industry?

1 Company	Price / Book	Estimated Growth	Market Cap
BNO Bionomics	0.3x	-36.0%	US$9.52m

No more companies available in this PB range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: ANR is expensive based on its Price-To-Book Ratio (8.2x) compared to the Australian Biotechs industry average (3x).

Price to Book Ratio vs Fair Ratio

What is ANR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ANR PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	8.2x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ANR's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Medical Developments International

AU$46.8m

Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.

MVP

AU$0.41

-2.4%

-46.1%

Neuren Pharmaceuticals

AU$1.6b

A biopharmaceutical company, develops drugs for the treatment of neurological disorders.

NEU

AU$12.32

-16.8%

-18.7%

AVITA Medical

US$343.1m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.98

5.0%

16.4%